Preview of Member Only Content
For full access: or Become a Member
Psychoactive medication and your client: Better living and (maybe) better law through chemistry
By David M. Siegel
Is your client taking psychoactive medication? The U.S. Supreme Court’s decision in Sell v. United States,1 makes this question more important than ever, and means that you must not only know the answer, but must also understand exactly what the medication is and how it could affect your client’s trial-related capacities. Sell makes clear that due process permits forced psychotropic medication of a criminal defendant in order to establish their competence to stand trial, however it severely limits the circumstances under which this should be permissible, and identifies four key considerations a court will have to address in order to approve medication. Satisfying the Sell standard to involuntarily medicate a pre-trial defendant will likely require more thorough hearings, involving more extensive fact development concerning the specific types of medication proposed, their potential side effects and treatment alternatives. Even if you believe that there are no competence issues in your c
Want to read more?
The Champion archive is reserved for NACDL members.
NACDL members, please login to read the rest of this article.
Not a member? Join now.
Or click here to see an overview of NACDL Member benefits.
See what NACDL members say about us.
To read the current issue of The Champion in its entirety, click here.
- Media inquiries: Contact NACDL's Director of Public Affairs & Communications Ivan J. Dominguez at 202-465-7662 or email@example.com
- Academic Requests: Full articles of The Champion Magazine are available for academic and research purposes in the WestLaw and LexisNexis databases.